Medicina
Departamento
University of Alberta
Edmonton, CanadáPublicaciones en colaboración con investigadoras/es de University of Alberta (16)
2019
-
Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing
PLoS ONE, Vol. 14, Núm. 7
-
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Antiviral Research, Vol. 170
2018
-
Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial
JAMA - Journal of the American Medical Association, Vol. 319, Núm. 1, pp. 38-48
-
Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations
Transplantation Reviews, Vol. 32, Núm. 1, pp. 36-57
2017
-
Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance
Journal of Clinical Virology, Vol. 90, pp. 57-63
-
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016
The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150
-
Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015
The Lancet, Vol. 390, Núm. 10091, pp. 231-266
-
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700
-
Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial)
Infectious Diseases, Vol. 49, Núm. 3, pp. 200-207
2016
-
Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations
Transplantation Reviews, Vol. 30, Núm. 3, pp. 119-143
2015
-
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
The Lancet, Vol. 385, Núm. 9963, pp. 117-171
-
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
The Lancet, Vol. 386, Núm. 9995, pp. 743-800
2012
-
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010
The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223
-
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010
The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196
2010
-
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation
Transplantation, Vol. 89, Núm. 7, pp. 779-795
2009
-
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients
American Journal of Transplantation, Vol. 9, Núm. 5, pp. 1205-1213